Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Murikama, Mm"'
Autor:
Schoels, Mm, Van Der Heijde, D, Breedveld, Fc, Burmester, Gr, Dougados, M, Emery, P, Ferraccioli, Gianfranco, Gabay, C, Gibofsky, A, Gomez Reino, Jj, Jones, G, Kvien, Tk, Murakami, M, Murikama, Mm, Nishimoto, N, Smolen, Js
Publikováno v:
Annals of the Rheumatic Diseases, 72(4), 583-589
Annals of the Rheumatic Diseases
Annals of the Rheumatic Diseases, Vol. 72, No 4 (2013) pp. 583-9
Annals of the Rheumatic Diseases
Annals of the Rheumatic Diseases, Vol. 72, No 4 (2013) pp. 583-9
Background Suppression of the immunoinflammatory cascade by targeting interleukin 6 (IL-6) mediated effects constitutes a therapeutic option for chronic inflammatory diseases. Tocilizumab is the only IL-6 inhibitor (IL-6i) licensed for rheumatoid art
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3dcd89f6b6a3c70daee2561a6377538e
https://hdl.handle.net/1887/98414
https://hdl.handle.net/1887/98414
Autor:
Schoels MM; Correspondence to Dr Monika M Schoels, 2nd Department of Internal Medicine, Center for Rheumatic Diseases, Hietzing Hospital, Wolkersbergenstrasse 1, Vienna 1130, Austria. monika.schoels@live.com, van der Heijde D, Breedveld FC, Burmester GR, Dougados M, Emery P, Ferraccioli G, Gabay C, Gibofsky A, Gomez-Reino JJ, Jones G, Kvien TK, Murakami M, Nishimoto N, Smolen JS
Publikováno v:
Annals of the rheumatic diseases [Ann Rheum Dis] 2013 Apr; Vol. 72 (4), pp. 583-9. Date of Electronic Publication: 2012 Nov 10.
